BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 29739809)

  • 1. Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein.
    Yamazaki S; Loi CM; Kimoto E; Costales C; Varma MV
    Drug Metab Dispos; 2018 Aug; 46(8):1200-1211. PubMed ID: 29739809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
    Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
    Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model.
    Yamazaki S; Johnson TR; Smith BJ
    Drug Metab Dispos; 2015 Oct; 43(10):1417-29. PubMed ID: 26180127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
    Abbas R; Leister C; El Gaaloul M; Chalon S; Sonnichsen D
    Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects.
    Abbas R; Hug BA; Leister C; Burns J; Sonnichsen D
    J Clin Pharmacol; 2011 Dec; 51(12):1721-7. PubMed ID: 21148045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects.
    Abbas R; Boni J; Sonnichsen D
    Drug Metab Pers Ther; 2015 Mar; 30(1):57-63. PubMed ID: 25803093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
    Prakash C; Fan B; Ke A; Le K; Yang H
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.
    Hsyu PH; Pignataro DS; Matschke K
    Eur J Clin Pharmacol; 2017 Jan; 73(1):49-56. PubMed ID: 27718000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
    Gu H; Dutreix C; Rebello S; Ouatas T; Wang L; Chun DY; Einolf HJ; He H
    Drug Metab Dispos; 2018 Feb; 46(2):109-121. PubMed ID: 29117990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
    Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
    Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
    Fenneteau F; Poulin P; Nekka F
    J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically Based Pharmacokinetic Modeling of Palbociclib.
    Yu Y; Loi CM; Hoffman J; Wang D
    J Clin Pharmacol; 2017 Feb; 57(2):173-184. PubMed ID: 27402157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically-Based Pharmacokinetic Predictions of the Effect of Curcumin on Metabolism of Imatinib and Bosutinib: In Vitro and In Vivo Disconnect.
    Adiwidjaja J; Boddy AV; McLachlan AJ
    Pharm Res; 2020 Jun; 37(7):128. PubMed ID: 32529309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach.
    Adiwidjaja J; Boddy AV; McLachlan AJ
    Br J Clin Pharmacol; 2020 Oct; 86(10):2080-2094. PubMed ID: 32250458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib.
    Adiwidjaja J; Boddy AV; McLachlan AJ
    Eur J Clin Pharmacol; 2022 Apr; 78(4):597-611. PubMed ID: 35048143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
    Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
    Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib.
    Abbas R; Hsyu PH
    Clin Pharmacokinet; 2016 Oct; 55(10):1191-1204. PubMed ID: 27113346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P-glycoprotein-cytochrome P450 3A4 dual substrates.
    Pan X; Yamazaki S; Neuhoff S; Zhang M; Pilla Reddy V
    CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1485-1496. PubMed ID: 34729944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically Based Pharmacokinetic Modeling for Maribavir to Inform Dosing in Drug-Drug Interaction Scenarios with CYP3A4 Inducers and Inhibitors.
    Chen G; Sun K; Michon I; Barter Z; Neuhoff S; Ghosh L; Ilic K; Song IH
    J Clin Pharmacol; 2024 May; 64(5):590-600. PubMed ID: 38009271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients.
    Einolf HJ; Zhou J; Won C; Wang L; Rebello S
    Drug Metab Dispos; 2017 Apr; 45(4):361-374. PubMed ID: 28122787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.